GSK Agrees to Buy Nuvalent for $10.6 Billion
GSK agreed to buy Nuvalent in a deal valued at $10.6 billion, adding a biotech firm that's developing treatments for lung cancer as the British pharmaceutical company seeks to rebuild its oncology franchise. Sam Fazeli of Bloomberg Intelligence has more.
_1417563_640x360_2503007299812-640x360.webp&w=3840&q=75)
_1417537_640x360_2502999619844-640x360.webp&w=3840&q=75)
_1417534_640x360_2503002179961-640x360.webp&w=3840&q=75)
_1417507_640x360_2503001155531-640x360.webp&w=3840&q=75)

_1417497_640x360_2502994499595-640x360.webp&w=3840&q=75)
_1417479_640x360_2502986819999-640x360.webp&w=3840&q=75)
_1417477_640x360_2502986307726-640x360.webp&w=3840&q=75)
_1417428_640x360_2502936131939-640x360.webp&w=3840&q=75)
_1417421_640x360_2502943811823-640x360.webp&w=3840&q=75)